Non Small Cell Lung Carcinoma clinical trials

Explore recruiting non small cell lung carcinoma clinical trials.

Recruiting non small cell lung carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Small Cell Lung Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Dose tapering and Early Discontinuation to InCreAse cosT-effictIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1 (NVALT-30 - Dedication-1)

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Study Investigating Tucatinib and Osimertinib Pharmacokinetics in Primary and Metastatic Brain Tumors: the STICK trial

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

Evaluating T Cell Changes and Activation in Cancer Patient Using Two PET Tracers (iRelate)

Netherlands

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase III, double-blind, randomized, placebo-controlled multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy (ADAURA)

Belgium, Germany, Sweden, Spain, Italy, Poland +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

OPTIMUNE-LUNG : INTEGRATIVE ANALYSIS OF THE TUMOR MICROENVIRONMENT AND OPTIMIZATION OF THE IMMUNOTHERAPY DURATION IN NON-SMALL CELL LUNG CANCER PATIENTS

France

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-label, Single-arm, Phase II, Multinational, Multicentre Study to Assess the Efficacy and Safety of 5 Years of Osimertinib in Participants withEpidermal Growth Factor Receptor Mutation-Positive Stage II-IIIB Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (TARGET)

Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Non Small Cell Lung Carcinoma trials by city

Non Small Cell Lung Carcinoma in Toronto Non Small Cell Lung Carcinoma in Vancouver Non Small Cell Lung Carcinoma in Montreal Non Small Cell Lung Carcinoma in Calgary Non Small Cell Lung Carcinoma in Edmonton Non Small Cell Lung Carcinoma in Ottawa Non Small Cell Lung Carcinoma in Winnipeg Non Small Cell Lung Carcinoma in Quebec City Non Small Cell Lung Carcinoma in Hamilton Non Small Cell Lung Carcinoma in Kitchener Non Small Cell Lung Carcinoma in London Non Small Cell Lung Carcinoma in Halifax Non Small Cell Lung Carcinoma in New York Non Small Cell Lung Carcinoma in Los Angeles Non Small Cell Lung Carcinoma in Chicago Non Small Cell Lung Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease